Who is sponsoring NCT07130799?

NCT07130799 is sponsored by Central Hospital, Nancy, France.

What drugs are being tested in NCT07130799?

Interventions in NCT07130799: Immunomonitoring.

What condition does NCT07130799 study?

NCT07130799 studies Intra-abdominal Infection, Critical Illness, Post-Op Infection, Immunization; Sepsis, Candida Sepsis.

Is NCT07130799 still recruiting?

NCT07130799 is currently recruiting now. Last updated 9 February 2026.

Last reviewed 2026-02-09 · How we verify

NCT07130799: CANDIRIS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Innate Immune Response Monitoring Via Monocyte HLA-DR in Severe Intra-abdominal Infections at Risk of Fungal Infection

Recruiting now Last updated 9 February 2026

What this trial tests

trial testing Immunomonitoring in Intra-abdominal Infection in 100 participants. Currently enrolling.

Timeline

14 November 2025

Primary endpoint
1 September 2026

1 March 2027

Quick facts

Lead sponsor	Central Hospital, Nancy, France
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	100
Start date	14 November 2025
Primary completion	1 September 2026
Estimated completion	1 March 2027
Sites	1 location across France

Drugs / interventions tested

Immunomonitoring — full drug profile →

Conditions studied

Intra-abdominal Infection — all drugs for Intra-abdominal Infection →
Critical Illness — all drugs for Critical Illness →
Post-Op Infection — all drugs for Post-Op Infection →
Immunization; Sepsis — all drugs for Immunization; Sepsis →

Sponsor

Central Hospital, Nancy, France

Who can join

18 and older, any sex, with Intra-abdominal Infection or Critical Illness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Intra-abdominal candidiasis (IAC) is a frequent and severe fungal infection in critically ill patients, often diagnosed late. Its pathophysiology remains unclear, particularly regarding why some patients develop invasive infection while others only show benign colonization. A potential explanation lies in the state of innate immunity. Monocyte HLA-DR expression, a recognized marker of immune suppression in critical care, may be transiently but profoundly reduced in non-immunocompromised patients who go on to develop IAC. This observational study aims to evaluate whether patients with IAC have greater innate immune dysfunction-assessed by HLA-DR expression-compared to those with severe bacterial intra-abdominal infections. The goal is to better understand the immune mechanisms involved and improve early risk stratification for IAC.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Intra-abdominal Infection

Currently open trials in the same condition.

NCT06304779 — The Effect of Continuous Intravenous Infusion of Lidocaine on PPCs and Prognosis in Emergency Surgical Patients With IAI · NA · active not recruiting
NCT05127109 — The PASTDUe Nutrition Ecosystem Project (PASTDUe) · Phase 4 · active not recruiting

Other Central Hospital, Nancy, France trials

Trials by the same sponsor.

NCT06452290 — PET Biomarker Study for Antidepressant Response Prediction in Major Depressive Disorder · NA · not yet recruiting
NCT07518498 — Hypnosis During Mechanical Ventilation Weaning · NA · not yet recruiting
NCT07471334 — Prospective Study of Postictal Psychotic Symptoms Occuring After Video-EEG Monitoring in Focal Epilepsies · NA · not yet recruiting
NCT07414667 — Primary Sjögren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification ( · not yet recruiting
NCT07415759 — Imaging of Electrical Properties by MRI: Investigation of Age-Related Changes · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07130799 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Central Hospital, Nancy, France
Last refreshed: 9 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07130799.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing